1. Home
  2. Detail

@blessing.joseph297:

Blessing Joseph
Blessing Joseph
Open In TikTok:
Region: NG
Tuesday 16 June 2026 10:35:09 GMT
156
23
1
1

Music

Download

No Watermark .mp4 (1.19MB) No Watermark(HD) .mp4 (1.19MB) Watermark .mp4 (1.19MB) Music .mp3

Comments

user7724023297223
user7724023297223 :
😏😏😏
2026-06-17 02:37:06
0
To see more videos from user @blessing.joseph297, please go to the Tikwm homepage.

Other Videos

Juneteenth with Keke Palmer feels like Houston is celebrating at full volume. #Juneteenth #KekePalmer #Houston #BlackCulture #CommunityVibes
Juneteenth with Keke Palmer feels like Houston is celebrating at full volume. #Juneteenth #KekePalmer #Houston #BlackCulture #CommunityVibes
#LIVEIncentiveProgram #ZeroToHero #PaidPartnership
#LIVEIncentiveProgram #ZeroToHero #PaidPartnership
No zipper. No buttons. No discomfort. #joggers #gym #tiktokshopmemorialday #DealsForYouDays #tiktokshopdealsforyoudays #thegympeople #buynow #womensfashion #BigComfy
No zipper. No buttons. No discomfort. #joggers #gym #tiktokshopmemorialday #DealsForYouDays #tiktokshopdealsforyoudays #thegympeople #buynow #womensfashion #BigComfy
Ele tá na minha maldade #vtzim #brawlstars
Ele tá na minha maldade #vtzim #brawlstars
Vycor Medical’s leadership team recently presented at the Life Sciences Virtual Investor Forum, during which the company provided details on its progress with the flagship ViewSite Brain Access System (VBAS). Vycor Medical, Inc. (OTCQB: VYCO) is a B2i Digital Featured Venture Company. See the complete profile at https://b2idigital.com/vycor-medical. The company’s clinical traction is now broad, and its technology is well-protected. As noted by CEO Peter Zachariou, “VBAS is a validated technology. It has been used in over 300 hospitals in the United States, and we have an international presence. The technology is protected by 46 granted patents and 11 pending patents in the U.S. and internationally.” Economics matter, too: “We estimate that hospitals save up to $6,000 per procedure using VBAS,” thanks to shorter operating times and quicker recoveries. Highlights from the presentation include a discussion of the following topics: Management alignment and disciplined growth: insiders own ~60% of the company and report being cash-operating positive. Expanding into new markets: Management estimates the intracerebral hemorrhage (ICH) opportunity is roughly twice the size of the tumor market. Two clinical studies, one being conducted in Switzerland and the other in the U.S., are currently underway. Growth opportunities: Vycor is well-positioned to scale organically and expand through strategic acquisitions. To learn more, watch the full replay at this link. In addition to VBAS, Vycor’s NovaVision® platform provides clinically supported vision-rehabilitation therapies for stroke and brain injury patients. With FDA-cleared or registered technologies and a strong clinical foundation, Vycor Medical is helping to improve outcomes in neurosurgery and neuro-rehabilitation. Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. Learn more about Vycor Medical at https://www.vycormedical.com/investment-highlights. For investor inquiries, please contact info@vycormedical.com. #VycorMedical #Neurosurgery #VBAS #VisionRestoration #B2iDigital @B2iDigital @DavidShapiro
Vycor Medical’s leadership team recently presented at the Life Sciences Virtual Investor Forum, during which the company provided details on its progress with the flagship ViewSite Brain Access System (VBAS). Vycor Medical, Inc. (OTCQB: VYCO) is a B2i Digital Featured Venture Company. See the complete profile at https://b2idigital.com/vycor-medical. The company’s clinical traction is now broad, and its technology is well-protected. As noted by CEO Peter Zachariou, “VBAS is a validated technology. It has been used in over 300 hospitals in the United States, and we have an international presence. The technology is protected by 46 granted patents and 11 pending patents in the U.S. and internationally.” Economics matter, too: “We estimate that hospitals save up to $6,000 per procedure using VBAS,” thanks to shorter operating times and quicker recoveries. Highlights from the presentation include a discussion of the following topics: Management alignment and disciplined growth: insiders own ~60% of the company and report being cash-operating positive. Expanding into new markets: Management estimates the intracerebral hemorrhage (ICH) opportunity is roughly twice the size of the tumor market. Two clinical studies, one being conducted in Switzerland and the other in the U.S., are currently underway. Growth opportunities: Vycor is well-positioned to scale organically and expand through strategic acquisitions. To learn more, watch the full replay at this link. In addition to VBAS, Vycor’s NovaVision® platform provides clinically supported vision-rehabilitation therapies for stroke and brain injury patients. With FDA-cleared or registered technologies and a strong clinical foundation, Vycor Medical is helping to improve outcomes in neurosurgery and neuro-rehabilitation. Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. Learn more about Vycor Medical at https://www.vycormedical.com/investment-highlights. For investor inquiries, please contact [email protected]. #VycorMedical #Neurosurgery #VBAS #VisionRestoration #B2iDigital @B2iDigital @DavidShapiro
#meatdefrost #CookingHacks #kitchentips #meattips #foodhack
#meatdefrost #CookingHacks #kitchentips #meattips #foodhack

About

Legal